1. rpereira07
2. MamisTrist
3. oxbum49791
4. WalkingDeader
5. latinoboyz4874
1.WalkingDeader 01/26/2018
UPGRADES SOON - Reports of EPS beat ranging from $0.02 to $0.04. Beats on revenues.
2.MamisTrist 01/22/2018
Good stuff!
3.rpereira07 01/25/2018
Wow!! ... More Awesome news for $NVS
4.oxbum49791 01/18/2018
Superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients
5.WalkingDeader 01/22/2018
Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period
6.MamisTrist 02/14/2018
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
7.oxbum49791 01/22/2018
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
8.rpereira07 01/26/2018
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
9.rpereira07 02/01/2018
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
10.813kimd 02/18/2018
Novartis AG is preparing to sell its U.S. generic pill business,
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW